NO312878B1 - Hudheftende farmasöytisk preparat, fremgangsmåte for fremstilling av samme, samt anvendelse av slike preparater - Google Patents
Hudheftende farmasöytisk preparat, fremgangsmåte for fremstilling av samme, samt anvendelse av slike preparater Download PDFInfo
- Publication number
- NO312878B1 NO312878B1 NO19983098A NO983098A NO312878B1 NO 312878 B1 NO312878 B1 NO 312878B1 NO 19983098 A NO19983098 A NO 19983098A NO 983098 A NO983098 A NO 983098A NO 312878 B1 NO312878 B1 NO 312878B1
- Authority
- NO
- Norway
- Prior art keywords
- estradiol
- skin
- relative humidity
- adhesive
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000853 adhesive Substances 0.000 title claims description 11
- 230000001070 adhesive effect Effects 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract description 24
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 21
- 229960005309 estradiol Drugs 0.000 claims abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 15
- 239000010410 layer Substances 0.000 claims abstract description 14
- 229930182833 estradiol Natural products 0.000 claims abstract description 11
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 239000012790 adhesive layer Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000011888 foil Substances 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 239000005022 packaging material Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003851 estradiol hemihydrate Drugs 0.000 claims description 3
- 238000004080 punching Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 2
- 239000011358 absorbing material Substances 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012432 intermediate storage Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19600347A DE19600347A1 (de) | 1996-01-08 | 1996-01-08 | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
| PCT/EP1996/005822 WO1997025077A1 (fr) | 1996-01-08 | 1996-12-23 | PREPARATION PHARMACEUTIQUE ADHERANT A LA PEAU, NOTAMMENT SYSTEME THERAPEUTIQUE TRANSDERMIQUE POUR LA LIBERATION DE 17-β-ESTRADIOL DANS L'ORGANISME HUMAIN |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983098L NO983098L (no) | 1998-07-03 |
| NO983098D0 NO983098D0 (no) | 1998-07-03 |
| NO312878B1 true NO312878B1 (no) | 2002-07-15 |
Family
ID=7782261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983098A NO312878B1 (no) | 1996-01-08 | 1998-07-03 | Hudheftende farmasöytisk preparat, fremgangsmåte for fremstilling av samme, samt anvendelse av slike preparater |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6267982B1 (fr) |
| EP (1) | EP0880366B1 (fr) |
| JP (1) | JP2000505071A (fr) |
| KR (1) | KR100476579B1 (fr) |
| CN (1) | CN1107525C (fr) |
| AT (1) | ATE205406T1 (fr) |
| AU (1) | AU721677B2 (fr) |
| CA (1) | CA2242577C (fr) |
| CZ (1) | CZ289291B6 (fr) |
| DE (2) | DE19600347A1 (fr) |
| DK (1) | DK0880366T3 (fr) |
| ES (1) | ES2164270T3 (fr) |
| HU (1) | HUP9901102A3 (fr) |
| IL (1) | IL125160A (fr) |
| MY (1) | MY129733A (fr) |
| NO (1) | NO312878B1 (fr) |
| NZ (1) | NZ325817A (fr) |
| PL (1) | PL187275B1 (fr) |
| SK (1) | SK282984B6 (fr) |
| WO (1) | WO1997025077A1 (fr) |
| ZA (1) | ZA97111B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623763B2 (en) * | 1996-01-08 | 2003-09-23 | Lts Lohmann Therape-System Ag | Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism |
| ATE526022T1 (de) * | 1998-04-20 | 2011-10-15 | Eisai R&D Man Co Ltd | Stabilisierte zusammenstellungen die benzimidazole enthalten |
| DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| WO2001064937A2 (fr) * | 2000-03-02 | 2001-09-07 | Mcgill University | Facteur inhibiteur de caspase et utilisations correspondantes |
| JP4989892B2 (ja) * | 2004-01-30 | 2012-08-01 | 久光製薬株式会社 | 貼付剤入り包装袋 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863738A (en) * | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
| ATE95059T1 (de) * | 1989-02-28 | 1993-10-15 | Teijin Ltd | Pflaster sowie dessen herstellung. |
| IT1253265B (it) * | 1991-11-25 | 1995-07-14 | Rotta Research Lab | Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo. |
| DE4223360C1 (fr) * | 1992-07-16 | 1993-04-08 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| DE4237453C1 (fr) * | 1992-11-06 | 1993-08-19 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| DE4405899A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Desogestrel |
| DE4429667C2 (de) * | 1994-08-20 | 1996-07-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
| DE4429664C2 (de) * | 1994-08-20 | 1997-09-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
-
1996
- 1996-01-08 DE DE19600347A patent/DE19600347A1/de not_active Withdrawn
- 1996-12-23 EP EP96944648A patent/EP0880366B1/fr not_active Expired - Lifetime
- 1996-12-23 CN CN96199544A patent/CN1107525C/zh not_active Expired - Fee Related
- 1996-12-23 JP JP9524813A patent/JP2000505071A/ja active Pending
- 1996-12-23 WO PCT/EP1996/005822 patent/WO1997025077A1/fr active IP Right Grant
- 1996-12-23 HU HU9901102A patent/HUP9901102A3/hu unknown
- 1996-12-23 US US09/101,720 patent/US6267982B1/en not_active Expired - Lifetime
- 1996-12-23 CZ CZ19982140A patent/CZ289291B6/cs not_active IP Right Cessation
- 1996-12-23 DK DK96944648T patent/DK0880366T3/da active
- 1996-12-23 AU AU13057/97A patent/AU721677B2/en not_active Ceased
- 1996-12-23 SK SK908-98A patent/SK282984B6/sk unknown
- 1996-12-23 CA CA002242577A patent/CA2242577C/fr not_active Expired - Fee Related
- 1996-12-23 NZ NZ325817A patent/NZ325817A/xx not_active IP Right Cessation
- 1996-12-23 KR KR10-1998-0705246A patent/KR100476579B1/ko not_active IP Right Cessation
- 1996-12-23 DE DE59607696T patent/DE59607696D1/de not_active Expired - Lifetime
- 1996-12-23 ES ES96944648T patent/ES2164270T3/es not_active Expired - Lifetime
- 1996-12-23 PL PL96327940A patent/PL187275B1/pl not_active IP Right Cessation
- 1996-12-23 AT AT96944648T patent/ATE205406T1/de active
- 1996-12-23 IL IL12516096A patent/IL125160A/xx not_active IP Right Cessation
-
1997
- 1997-01-06 MY MYPI97000032A patent/MY129733A/en unknown
- 1997-01-07 ZA ZA9700111A patent/ZA97111B/xx unknown
-
1998
- 1998-07-03 NO NO19983098A patent/NO312878B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6267982B1 (en) | 2001-07-31 |
| AU721677B2 (en) | 2000-07-13 |
| KR19990077110A (ko) | 1999-10-25 |
| WO1997025077A1 (fr) | 1997-07-17 |
| HUP9901102A3 (en) | 1999-11-29 |
| CZ214098A3 (cs) | 1998-11-11 |
| DE19600347A1 (de) | 1997-07-10 |
| PL187275B1 (pl) | 2004-06-30 |
| SK90898A3 (en) | 1999-01-11 |
| ZA97111B (en) | 1997-08-18 |
| NO983098L (no) | 1998-07-03 |
| CA2242577C (fr) | 2006-06-06 |
| CZ289291B6 (cs) | 2001-12-12 |
| HUP9901102A2 (hu) | 1999-08-30 |
| DK0880366T3 (da) | 2001-12-27 |
| IL125160A0 (en) | 1999-01-26 |
| ES2164270T3 (es) | 2002-02-16 |
| CN1107525C (zh) | 2003-05-07 |
| NO983098D0 (no) | 1998-07-03 |
| DE59607696D1 (de) | 2001-10-18 |
| IL125160A (en) | 2003-01-12 |
| EP0880366B1 (fr) | 2001-09-12 |
| CN1207049A (zh) | 1999-02-03 |
| ATE205406T1 (de) | 2001-09-15 |
| MY129733A (en) | 2007-04-30 |
| SK282984B6 (sk) | 2003-01-09 |
| CA2242577A1 (fr) | 1997-07-17 |
| JP2000505071A (ja) | 2000-04-25 |
| EP0880366A1 (fr) | 1998-12-02 |
| KR100476579B1 (ko) | 2005-09-26 |
| PL327940A1 (en) | 1999-01-04 |
| NZ325817A (en) | 1999-01-28 |
| AU1305797A (en) | 1997-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5725874A (en) | Solubilizer and external preparations containing the same | |
| US20040028726A1 (en) | Transdermal systems for the delivery of clonidine | |
| EP0943330A1 (fr) | Timbre percutane | |
| JP5111710B2 (ja) | 安定化した過飽和経皮治療吸収基材システム | |
| JPH07138153A (ja) | 有効薬剤の経皮供給 | |
| US5252588A (en) | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation | |
| US5997897A (en) | Process for the production of a transdermal therapeutic system comprising the active substance 17-β-estradiol (anhydrous) | |
| JP4466977B2 (ja) | 経皮的治療システム | |
| AU2004206783B2 (en) | Formulation and methods for the treatment of thrombocythemia | |
| JP2006503877A (ja) | エペリゾン、トルペリゾン又はそれらの塩を含む経皮製剤 | |
| NO312878B1 (no) | Hudheftende farmasöytisk preparat, fremgangsmåte for fremstilling av samme, samt anvendelse av slike preparater | |
| US6623763B2 (en) | Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism | |
| US5902602A (en) | Estradiol-TTS having water-binding additives | |
| EP2068847B1 (fr) | Élaboration et composition de système d'administration médicamenteuse transdermique de méloxicam | |
| WO2000076485A1 (fr) | Preparation sensible a l'humidite du type a absorption percutanee | |
| EP1477189A1 (fr) | Processus de production de moulages d'adhesif autocollant constitue de polymeres reticules comme composant principal | |
| KR100403051B1 (ko) | 음낭 외 피부에 적용가능한 남성호르몬 경피흡수 패취제 | |
| JPH0825881B2 (ja) | エストラジオール含有貼付剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |